UPDATE (article originally published on June 6th, 2016): Sygnis successfully completes Rights Offering and Private Placement and secured the acquisition of Expedeon Holdings Ltd. on July 15th, 2016. See the end of the article for more details.
Headquartered in Germany and Spain, Sygnis develops products for genomic research, such as kits to amplify DNA and systems to ‘convert’ RNA into DNA – making RNA analysis easier.
Sygnis also eyed the emerging proteomics field. It developed Double Switch (now licensed to Thermo Fisher), a tool to detect and quantify protein interaction – an added layer of complexity in biology that cannot be ‘seen’